---

A case of cyclophosphamide-induced posterior reversible encephalopathy syndrome: Is it dose-related side effect?

Full Text PDF Share on Facebook Share on Twitter

---

Case Report

Author Details : Theeb Osama Sulaiman*, Ahmed K A Yasin, Abdellatif Ismail

Volume : 1, Issue : 2, Year : 2022

Article Page : 103-107

Suggest article by email

Abstract

We reported a case of cyclophosphamide (CYP)-induced posterior reversible encephalopathy syndrome (PRES) in a 26-year-old previously healthy male patient who was presented to the emergency department with a history of fever, shortness of breath, and hemoptysis. After extensive investigations, including bronchoscopy and autoimmune screening, he was diagnosed with renal-pulmonary syndrome. The diagnosis of CYP-related PRES was based on the development of neurological clinical picture supported by magnetic resonance imaging findings. The dose of CYP was decreased to 75 mg/day, and the patient’s symptoms improved after 3 days.

Keywords:  Antineutrophil cytoplasmic antibody, Cyclophosphamide, Posterior reversible encephalopathy syndrome, Renal-pulmonary disease

How to cite : Sulaiman T O, Yasin A K A, Ismail A, A case of cyclophosphamide-induced posterior reversible encephalopathy syndrome: Is it dose-related side effect?. Yemen J Med 2022;1(2):103-107

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International, which allows others to remix, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.